MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Zymeworks Inc.

< Previous 1 2 3 4 5 Next >
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Additional Leadership Appointments
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Added to Nasdaq Biotechnology Index
From Zymeworks Inc.
Via GlobeNewswire
Tickers NBI ZYME
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story